EMA Prepares For Launch Of PRIME Priority Medicines Scheme
This article was originally published in SRA
Executive Summary
On March 7, the European Medicines Agency is to launch its keenly awaited PRIME (priority medicines) scheme, which is intended to support the development of medicines for patients with no treatment options or that offer a major advantage over existing drugs.
You may also be interested in...
'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context
EMA official gives perspectives on how PRIME and adaptive pathways compare, and how they fit with other programs such as conditional authorization.
2020 Sees Sharp Rise In EU New Drug Approvals
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: